AffiliationCancer Research UK Leukaemia Biology Laboratory, Paterson Institute for Cancer Research, The University of Manchester, Manchester, UK.
MetadataShow full item record
AbstractHuman acute myeloid leukemias (AMLs) are sustained by leukemic stem cells (LSCs) that generate through aberrant differentiation the blast cells that make up the bulk of the malignant clone. LSCs were first identified as rare cells with an immunophenotype shared with normal hematopoietic stem cells (HSCs). However, refinements of xenotransplantation assays, alternative methods of quantitation and syngeneic murine models have all led to an appreciation that LSCs display marked variability in frequency, immunophenotype and differentiation potential, both between and even within leukemias. Insights from next-generation sequencing efforts have dramatically extended understanding of the mutational landscape and clonal organization of AML and have added an additional layer of complexity to the biology of LSCs: a requirement to consider the effect of the various recurrently occurring genetic lesions in AML on the initiation and maintenance of leukemic subclones. Despite these advances, cure rates in AML remain substantially unchanged in recent years. A renewed focus on the biological properties of chemotherapy-resistant LSCs, a cellular entity of prime clinical importance, will be required to develop additional therapeutic strategies to enhance patient outcomes.
CitationThe variety of leukemic stem cells in myeloid malignancy.2013 Oncogene
- Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.
- Authors: Kikushige Y, Miyamoto T
- Issue date: 2015
- Right on target: eradicating leukemic stem cells.
- Authors: Krause DS, Van Etten RA
- Issue date: 2007 Nov
- [Recent progress in leukemic stem cell research for childhood leukemia].
- Authors: Eguchi M, Eguchi-Ishimae M, Ishii E
- Issue date: 2015 Oct
- [Acute myeloid leukemia stem cells from genomic and immunological perspectives].
- Authors: Goyama S
- Issue date: 2020
- Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms.
- Authors: Prick J, de Haan G, Green AR, Kent DG
- Issue date: 2014 Oct